Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Affiliations

• ¹ Health Division, Pharmacy and Pharmacology Department, Maccabi Healthcare Services, Tel-Aviv, Israel.
• ² Clinical Pharmacology and Toxicology Unit, Shamir Medical Center (Assaf Harofeh), Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
• ³ The Institute of Clinical Pharmacology and Toxicology, Internal Medicine A, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
• ⁴ Clinical Pharmacology Unit, Kaplan Medical Center, Rehovot, Israel, Affiliated to The Hebrew University of Jerusalem, Jerusalem, Israel.
• ⁵ Adelson School of Medicine, Ariel University, Ariel, Israel.
• ⁶ Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
• ⁷ Clinical Pharmacology Unit, Haemek Medical Center, Afula, Israel, Affiliated to The Bruce Rapapport School of Medicine, Technion, Israel.